CFS 1500 C for fast capsule filling

Published: 10-Feb-2010
Manufacturing Packaging Drug Delivery Pharmaceutical

An automated CFS 1500 C (containment) capsule filling and sealing system is now available from Capsugel, of Cambridge, UK, to provide rapid and safe filling and sealing of capsules containing lipid-based formulations or potent compounds for use in early phase clinical trials.

An automated CFS 1500 C (containment) capsule filling and sealing system is now available from Capsugel, of Cambridge, UK, to provide rapid and safe filling and sealing of capsules containing lipid-based formulations or potent compounds for use in early phase clinical trials.

The CFS 1500 C, which uses Capsugel's Licaps drug delivery technology, offers many of the timesaving benefits of the established CFS 1200. Additionally, it has accessible moving parts, which can be removed for manual or auto washer cleaning.

The CFS 1500 C has a throughput of 1,500 filled and sealed capsules per hour and is scalable to commercial manufacturing using the LEMS 70 liquid encapsulation micro-spray sealing system, which is capable of sealing up to 70,000 capsules per hour.

With the LEMS 70 and Licaps capsules, the CFS 1500 C can fill and seal capsules with a robust, impervious seal.

New software provides the CFS 1500 C with greater functionality and a weigh cell feature measures the weight of each filled capsule to ensure compliance with 21 CFR part 11.




  • Companies:
  • Lonza
See more

You may also like

Manufacturing

RION engages Lonza to scale manufacturing exosome based therapeutics

Read more
Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions

Trending Articles

  1. Agility, scale and trust: the outsourcing model driving pharma forward Outsourcing in the pharmaceutical industry has long been viewed as a matter of convenience and a way to ease short-term capacity pressures or delay the decision to invest in costly new facilities. That framing no longer fits
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Human-machine symbiosis: why Industry 5.0 is the future of pharmaceutical manufacturing Industry 5.0 is reshaping pharmaceutical manufacturing by fostering human-machine collaboration, addressing workforce shortages and making advanced automation accessible to all through innovative models such as robot rental
  3. Rezon Bio launches as European biologics CDMO with mirrored sites in Poland New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
  4. RION engages Lonza to scale manufacturing exosome based therapeutics Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

RION engages Lonza to scale manufacturing exosome based therapeutics

Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
Manufacturing

Lonza publishes updated 2024 financials ahead of One Lonza reporting

New CDMO platform structure supports upcoming half-year 2025 results
Manufacturing

Lonza launches Design2Optimise platform to streamline API development

The Design2Optimise platform contributes to improved efficiencies and timelines to clinical trials of small molecule APIs
Manufacturing

Ethris and Lonza collaborate to develop spray-dried mRNA vaccines for respiratory disease prevention

Collaboration is part of Ethris’ strategy to develop spray-dried mucosal mRNA vaccines that are stable at room temperature and capable of generating a localised immune response, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), including a first candidate against influenza
Drug Delivery

Lonza and Ethris team up to develop mRNA vaccines for respiratory diseases

The two hope to produce a temperature-stable mRNA vaccine for influenza, which may promote mucosal immunity through its nasal delivery system
Manufacturing

Lonza implements its simplified and streamlined operating model

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Manufacturing

Lonza delivers solid 2024 performance

Lonza delivers solid 2024 performance with CER sales in line with prior year and 29.0% margin
Subscribe now